Trials / Terminated
TerminatedNCT00796484
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of XL888 in subjects with solid tumors. XL888 is a potent and selective inhibitor of HSP90, a key component of a molecular chaperone complex that promotes the conformational maturation and stabilization of diverse client proteins. Many HSP90 client proteins play critical roles in signaling pathways implicated in tumor cell growth, proliferation, and survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL888 | Administered orally |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2008-11-24
- Last updated
- 2015-08-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00796484. Inclusion in this directory is not an endorsement.